CNCR Loncar Cancer Immunotherapy ETF
Quote as of Jul 02, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 8.88 | Day Range | 9.02 – 9.02 |
| 52-Week Range | 7.88 – 16.27 | Volume | 0 |
| Avg Volume | 2.15K | AUM | $12.7M (Aug 26, 2026) |
| Expense Ratio | 0.79% | Yield (TTM) | — |
| NAV | 13.68 | Premium/Discount | -34.06% indicative |
| Inception | Oct 14, 2015 | Holdings | 31 |
| Issuer | — | Exchange | NASDAQ |
| Category | Biotech | Index Tracked | Not stated in source data |
| CUSIP | 26922A826 | ISIN | US26922A8264 |
| Management | Not stated in source data | ||
About this ETF
The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.
Description from the fund data provider · profile as of Aug 26, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | -11.31% | -16.40% | -36.25% | -26.73% | -38.81% | -14.20% | -19.13% | — | -10.07% |
| Total return | -11.31% | -16.40% | -36.25% | -26.73% | -38.81% | -14.20% | -17.79% | — | -9.12% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Jun 03, 2025. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.79% | Annual cost of a $10,000 investment | $79.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Apr 17, 2023 — portfolio reporting date from the data provider; holdings are not live positions. 31 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | Instil Bio, Inc. | TIL | 3.59% | 93.23K | $963.4K |
| 2 | Replimune Group, Inc. | REPL | 3.54% | 47.19K | $950.0K |
| 3 | Iovance Biotherapeutics, Inc. | IOVA | 3.47% | 67.48K | $931.2K |
| 4 | Zymeworks Inc. | ZYME | 3.45% | 41.55K | $925.8K |
| 5 | argenx SE | ARGX | 3.42% | 5.06K | $917.8K |
| 6 | Genmab A/S | GMAB | 3.42% | 35.79K | $917.8K |
| 7 | AstraZeneca PLC | AZN | 3.39% | 26.54K | $909.7K |
| 8 | Bristol-Myers Squibb Company | BMY | 3.39% | 23.17K | $909.7K |
| 9 | CRISPR Therapeutics AG | CRSP | 3.39% | 12.62K | $909.7K |
| 10 | Merck & Co., Inc. | MRK | 3.37% | 20.51K | $904.4K |
| 11 | Nektar Therapeutics | NKTR | 3.37% | 87.53K | $904.4K |
| 12 | Xencor, Inc. | XNCR | 3.37% | 41.93K | $904.4K |
| 13 | Regeneron Pharmaceuticals, Inc. | REGN | 3.36% | 2.94K | $901.7K |
| 14 | Fate Therapeutics, Inc. | FATE | 3.33% | 17.66K | $893.6K |
| 15 | Gilead Sciences, Inc. | GILD | 3.33% | 22.54K | $893.6K |
| 16 | Arcus Biosciences, Inc. | RCUS | 3.32% | 62.77K | $890.9K |
| 17 | Atara Biotherapeutics, Inc. | ATRA | 3.30% | 108.60K | $885.6K |
| 18 | Trillium Therapeutics Inc. | TRIL | 3.29% | 160.99K | $882.9K |
| 19 | Rubius Therapeutics, Inc. | RUBY | 3.29% | 59.29K | $882.9K |
| 20 | Allogene Therapeutics, Inc. | ALLO | 3.29% | 60.62K | $882.9K |
| 21 | bluebird bio, Inc. | BLUE | 3.28% | 46.08K | $880.2K |
| 22 | ImmunityBio, Inc. | IBRX | 3.28% | 104.74K | $880.2K |
| 23 | I-Mab | IMAB | 3.25% | 21.30K | $872.2K |
| 24 | IGM Biosciences, Inc. | IGMS | 3.23% | 16.72K | $866.8K |
| 25 | Shattuck Labs, Inc. | STTK | 3.23% | 53.96K | $866.8K |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | — | Paid (last 12 months) | — |
| Frequency | Annual | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Dec 29, 2021 | Last payment | $1.8530 (Dec 31, 2021) |
| Growth 1Y | — | Growth 3Y / 5Y (ann.) | — / — |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Dec 29, 2021 | Dec 30, 2021 | Dec 31, 2021 | $1.8530 |
| Dec 30, 2020 | Dec 31, 2020 | Jan 04, 2021 | $0.2880 |
| Dec 28, 2017 | Dec 29, 2017 | Jan 02, 2018 | $0.3500 |
| Dec 29, 2015 | Dec 31, 2015 | Jan 04, 2016 | $0.1060 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | — / — | Sharpe 1Y / 3Y | — / — |
| Max drawdown 1Y / 3Y | — / — | Sortino 1Y | — |
| Beta vs S&P 500 (3Y) | 1.21 | Correlation vs S&P 500 (1Y) | — |
| Downside deviation 1Y | — | Risk-free rate used | 3.72% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Aug 26, 2026. Formulas →
Liquidity
| Volume today | 0 | Average volume | 2.15K |
| AUM | $12.7M | Premium/Discount | -34.06% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for CNCR
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.